Daniel G. Petereit

TL;DR: In this article, the authors present guidelines for using high-dose-rate brachytherapy in the management of patients with cervical cancer, taking into consideration the current availability of resources in most institutions.

TL;DR: The results suggest that prolongation of treatment time is associated with decreased local control and survival in patients with cervical carcinoma, consistent with emerging data from other institutions.

TL;DR: A comparative community-based participatory research project in which newly-diagnosed cancer patients were prospectively surveyed using novel scales for medical mistrust and satisfaction with health care, and race was the only factor found to be significantly predictive of higher mistrust and lower satisfaction scores.

TL;DR: A dose response relationship could not be identified for either tumor control nor late tissue complications, and these findings do not necessarily question the validity of the linear quadratic model, as much as they question the quality of the current HDR brachytherapy literature.

TL;DR: The mouse model was used to identify minichromosome maintenance protein 7 (MCM7), an E2F-induced cellular DNA replication factor, as a novel biomarker for cervical cancer, and strong, full thickness staining for MCM7 was seen selectively in the epithelium of high-grade intraepithelial lesions and in frank cancer.